SMi's 2nd Annual Orphan Drugs & Rare Diseases Conference, 14 - 15 October 2013, London

Date: Aug-09-2013Join SMi for their 2nd Annual Orphan Drugs & Rare Diseases Conference as they showcase world leading experts speaking inclusively on the orphan drug industry featuring cutting edge research via case studies taking place in previously untreatable patients. The conference will highlight current regulatory policies involving the FDA & EMA, new drug discoveries and partnerships in clinical trials and drug development with patient groups.

Last year's delegates say: "Excellent schedule, good variety of speakers, 2012 was fantastic, looking forward to the 2013 event!"


This year's agenda includes a 'Big Pharma Spotlight Session', from Pfizer, GlaxoSmithKline, Baxter, London School of Economics and Santhera Pharmaceuticals, highlighting where current pipelines stand and where the next blockbuster will be treating rare diseases, including discussions on HTA and pricing issues currently being implemented after recent reforms in Europe. The event is supported by NovaBiotics Ltd. and Clinigen Group.

Key Reasons to Attend:

Review through a unique 'Big Pharma Spotlight' session what drugs are finishing late stage clinical trials and where pipelines currently lead
Discover how market access and HTA are affecting Orphan Drug releases
Review optimal targeting for your new drug with expert analysis in patient selection and recruitment
Learn from case studies of new molecules in clinical trials
Analyse current funding options; including financial and economic reimbursement for the clinical development of drugs

Keynote Speakers Include:

Kevin Lee, CSO, Rare Disease Research Unit, Pfizer
Tony Hall, Founder, Findacure Foundation
Adrien Lamoine, Director, GlaxoSmithKline
Fernando Royo, VP, International Government Affairs, Genzyme
Camille Métais, Sr Regulatory Affairs Manager, Alexion Pharma
David King, Director, Regulatory Policy and Intelligence, Novo Nordisk

The conference will be followed by an interactive workshop "Applications to Market Access in Orphan Drugs" hosted by Tony Hall, Founder, Findacure Foundation.

For the full conference programme and further information please visit:
 www.smi-online.co.uk/2013orphandrugs59.asp

Alternatively contact Jonathan Collins on +44 (0)20 7827 6734 or email: jcollins@smi-online.co.uk

Sponsorship opportunities are available for this event, please contact Karl Barnard on +44(0) 20 7827 6020 or email: kbarnard@smi-online.co.uk

Contact for media-partners: Catarina Almeida, calmeida@smi-online.co.uk, +44 (0) 20 7827 6088.

Courtesy: Medical News Today Note: Any medical information available in this news section is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional.